Positive impact of Beyfortus on hospitalizations due to RSV

Recent results show a significant reduction in respiratory syncytial virus (RSV) hospitalizations with Beyfortus. In Spain, the use of Beyfortus resulted in a 70.2% decrease in infant hospitalizations for the 2024-2025 season. In the UK, another program using RSVpreF showed a 28.3% decrease. One study found that Beyfortus maintained 83% efficacy over six months, surpassing the typical RSV season.

These data come from the REACH study and will be presented at ESPID. They highlight the importance of Beyfortus in preventing respiratory illnesses in infants. Administration of this antibody provides long-lasting and direct protection without activating the immune system, according to the HARMONIE study published in The Lancet.